Cardiff Oncology

Actuate Therapeutics' elraglusib reduced death risk by 37% in a Phase I/II metastatic pancreatic cancer trial, doubling one-year survival rate to 43.6% in the treatment arm vs 22.5% in the control arm. The company plans a Phase III study based on these encouraging results.

Cardiff Oncology's onvansertib, a PLK1 inhibitor, showed 64% ORR in a phase II study for first-line RAS-mutated mCRC, with 57% overall ORR. The 30 mg dose demonstrated greater tumor size reduction and similar safety profiles. The company plans a phase III study based on these results.

Cardiff Oncology reports promising Phase 2 trial results for onvansertib in first-line RAS-mutated metastatic colorectal cancer, showing higher overall response rates compared to standard treatments alone.

Cardiff Oncology announced positive Phase II data for onvansertib in RAS-mutated mCRC, showing 64% ORR in the 30mg dose arm. The stock price surged 50% following the results, and the company plans to use $40m from an oversubscribed offering to fund clinical costs and other purposes.

New Amsterdam Pharma's CETP inhibitor succeeded in Phase 3 trials, GSK partnered with Relation for fibrotic disease and osteoarthritis drugs, Cardiff Oncology's CRDF-004 showed tumor shrinkage in metastatic colon cancer patients, and Cure Ventures launched Tasca Therapeutics with $52 million for cancer therapies. GSK's Blenrep showed improved survival in multiple myeloma patients, J&J's Darzalex may prevent myeloma in high-risk patients, and Uniqure received FDA approval to seek accelerated approval for Huntington's disease gene therapy.

DelveInsight's report on KRAS Inhibitors covers market trends, epidemiology, and pipeline developments in the US, EU4, UK, and Japan. The market is driven by cancer incidence and personalized treatments, with key companies like Novartis, Roche, and Verastem Oncology leading in KRAS inhibitor therapies.

PhD biochemist educates on science behind biotech investments, emphasizing due diligence to avoid pitfalls. No stock positions or compensation received for this article.

Cancer has become more manageable due to tailored treatments, with leaders in oncology pushing for genetic insights and data research. This year's Cancer Care Visionaries include Dr. Hesham Abdullah, Jason Bock, Arnon Chait, Raffaele Colombo, Dr. Yusri Elsayed, Mark Erlander, Dr. Marjorie Green, Raquel Izumi, Dr. Biljana Naumovic, Dr. Amita Patnaik, Dr. Mary Pinder-Schenck, Amoolya Singh, and AmirAli Talasaz, each contributing unique perspectives on cancer therapy and leadership.

Nivolumab (Opdivo) plus standard chemotherapy (AVD) showed longer progression-free survival (PFS) and better side-effect profile compared to brentuximab vedotin (Adcetris) plus AVD in advanced-stage Hodgkin's lymphoma patients, according to the SWOG S1826 trial.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.